A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

Prior treatment

• Previous treatment cell or gene therapy.
• Treatment with another oligonucleotide within 6 months of informed consent (not including COVID-19 RNA vaccines).
• If on any of the following treatments (growth hormone, testosterone or givinostat), participants must be on a stable regimen and must plan to maintain it for the duration of the study. Participants will be excluded if regimen stability prior to informed consent is as follows:

Lab values

• Lab values outside of the protocol specified range at Screening

Other

• Less than 1 month, for growth hormone and/or testosterone
• Less than 6 months for givinostat

• Ambulatory males with clinical and genetic diagnosis of DMD
• Acceptable genetic test confirming dystrophin gene mutation amenable to exon 44 skipping
• 7 to 16 years of age at time of consent
• TTR and NSAA assessment completed within the protocol specified parameters at Screening
• On a stable regimen of corticosteroids (including Vamolorone) for at least 6 months prior to Day 1. Steroid regimen must be anticipated to remain stable.